These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24267247)

  • 1. 10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits.
    Elseweidy MM; Abdallah FR; Younis NN; Aldohmy S; Kassem HM
    Atherosclerosis; 2013 Dec; 231(2):334-40. PubMed ID: 24267247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione.
    El-Seweidy MM; Sarhan Amin R; Husseini Atteia H; El-Zeiky RR; Al-Gabri NA
    Biomed Pharmacother; 2019 Feb; 110():456-464. PubMed ID: 30530048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition.
    Elseweidy MM; Amin RS; Atteia HH; El-Zeiky RR; Al-Gabri NA
    Appl Biochem Biotechnol; 2018 Dec; 186(4):805-815. PubMed ID: 29740798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent.
    El-Seweidy MM; Asker Mel-S; Eldahmy SI; Atteia HH; Abdallah MA
    J Thromb Thrombolysis; 2015 Feb; 39(2):196-202. PubMed ID: 25388083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM; Davidson MH; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic roles of 10-dehydrogingerdione and/or pentoxifylline against calcium deposition in aortic tissues of high dietary cholesterol-fed rabbits.
    Elseweidy MM; Mohamed HE; Elrashidy RA; Atteia HH; Elnagar GM; Ali AE
    Mol Cell Biochem; 2019 Mar; 453(1-2):131-142. PubMed ID: 30173373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CETP and oxidized LDL levels increase in dyslipidemic subjects.
    Wang J; Gu Q; Li K; Zhang C
    Clin Biochem; 2007 Sep; 40(13-14):995-9. PubMed ID: 17658505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
    Kühnast S; van der Tuin SJ; van der Hoorn JW; van Klinken JB; Simic B; Pieterman E; Havekes LM; Landmesser U; Lüscher TF; Willems van Dijk K; Rensen PC; Jukema JW; Princen HM
    Eur Heart J; 2015 Jan; 36(1):39-48. PubMed ID: 25142968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
    Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
    J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
    de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
    Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
    Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
    Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The conformation and CETP inhibitory activity of [10]-dehydrogingerdione isolated from Zingiber officinale.
    Choi SY; Park GS; Lee SY; Kim JY; Kim YK
    Arch Pharm Res; 2011 May; 34(5):727-31. PubMed ID: 21656357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.
    Ge S; Zhou G; Cheng S; Liu D; Xu J; Xu G; Liu X
    Atherosclerosis; 2009 Jul; 205(1):74-9. PubMed ID: 19110249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects.
    Qin Y; Xia M; Ma J; Hao Y; Liu J; Mou H; Cao L; Ling W
    Am J Clin Nutr; 2009 Sep; 90(3):485-92. PubMed ID: 19640950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.